MVIR: Pipeline expansion, clinical progress, and robust funding position drive optimistic outlook

Strong pipeline progress with MIV-711 advancing into phase II for OI after new funding and FDA orphan drug status, Fostrox liver cancer study on track, and partnered VBX-1000 showing promising animal health results. Cash runway extends into 2028.

Based on Medivir AB [MVIR] Q4 2025 Audio Transcript — Feb. 18 2026